Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

erapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

About Eisai Inc.Eisai Inc. was established in 1995 and is ranked among the top-25 US pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the US pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes US-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/us.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of lorcaserin; the response to the CRL for the lorcaserin NDA, potential approval of lorcaserin and related plans and activities; the Eisai collaboration and potential activities thereunder; lorcaserin's patent coverage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
(Date:5/22/2015)... May 22 2015 /CNW/ - The Taskforce representing ... of all the hard work that the Minister and Health ... months. This program recognizes the needs of the thalidomide survivors, ... $75,000 a year, tax free, with annual adjustments for inflation. ... for annual payments of $100,000 based on the severity of ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... BLUE BELL, Pa., Feb. 2, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... a scientific paper in the journal Human Vaccines ... of Inovio,s SynCon™ DNA vaccine for prostate cancer targeting ...
... LIONVILLE, Pa., Feb. 1, 2011 West Pharmaceutical Services, Inc. ... attend the UBS 21st Annual Global Healthcare Services Conference in ... business and outlook on Tuesday, February 8, 2011 at 1:00 ... Company,s presentation, as well as a copy of the presentation ...
Cached Medicine Technology:Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 2Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 3Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 4Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 5
(Date:5/23/2015)... 2015 Add High-Quality prismatic refractions into footage ... , It's as simple as dragging and dropping footage into ... for full effect. , Including over 80 stunning flares, ... sensors making this the ultimate bundle for adding prismatic refractions ... this package are movie files designed for Final Cut Pro ...
(Date:5/22/2015)... Utah (PRWEB) May 22, 2015 Mountain Point ... host a ribbon cutting ceremony on Friday, May 29, 2015 ... p.m. to 6 p.m. The new medical center, set to ... North Triumph Boulevard, Lehi, UT 84043. , “The opening ... our team and the Utah County community,” said Kent Loosle, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... NRL: THE NEW STANDARDIZED SOURCE MATERIAL FOR THE PRODUCTION ... PRODUCTS USING ... Technology Limited has invited,Vystar Corporation to present its revolutionary ... Conference 2008 in Madrid in,January. "Vytex(TM) Natural Rubber ...
... Spain: In a surprising finding, American scientists have found ... as well as their single counterparts in certain aspects ... study, presented today (Wednesday) at the European Cancer Conference ... 489 patients with Barretts oesophagus, a non-cancerous condition linked ...
... that attacks cancer in an entirely new way has ... the disease and prolonging the lives of patients. , ... Conference (ECCO 14) in Barcelona found that giving the ... the amount of time patients survived without progression of ...
... and Vicksburg Plants Recognized as Premier,Facilities by the Association for ... ... Magazine, BATESVILLE, Ind., Sept. ... Hillenbrand Industries (HB),announced that its two metal manufacturing facilities and ...
... Proposals and Variations, LOS ANGELES, Sept. ... a leading e-health Wi-Fi PDA technology provider, ... and EMR applications,and the distributor of life ... products, announced today that its Board of ...
... newly incorporated subsidiary of Genomatix Software GmbH, has announced that ... the NCI/NIH for the fourth consecutive year. This years renewal ... was executed entirely between the US company and the NCI/NIH ... with our progress in putting the US company on its ...
Cached Medicine News:Health News:Global Latex Conference to Showcase Vytex(TM) NRL 2Health News:Married esophageal cancer patients fare worse in some quality of life aspects than single patients 2Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations 2Health News:Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations 3Health News:InstaCare Corp. Reviewing M&A Plans 2
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... silicone or Silitek, ACMI Single J ... healing after surgery. Following cystectomy, the ... supports the ileal intestinal anastomosis, and ... leakage. Following ureteroscopy, the Single J ...
... The V-Max™ Roller Bar Electrode provides ... and improve visibility during TURP procedures. The ... surface with holes. The holes have circular ... tissue ablation. This patented design was developed ...
Medicine Products: